drugset / Trial / NCT01265433
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Phase 2
Completed
41 enrolled
Sellas Life Sciences Group
United States Department of Defense · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Study of galinpepimut-S, a Wilms Tumor-1 (WT1) vaccine, to see if it delays or prevents the mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth.
Timeline
- Start
- 2010-12-21
- Primary completion
- 2016-11-30
- Completion
- 2017-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galinpepimut-S | Vaccine | — | Subcutaneous |
| Background | Montanide | Other / unclassified | 1 ml | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | 70 ug | Subcutaneous |